Technology | EP Mapping and Imaging Systems | July 01, 2019

VIVO 3-D Cardiac Mapping System Cleared by FDA

New non-invasive cardiac imaging system from Catheter Precision offers higher accuracy

VIVO 3-D Cardiac Mapping System Cleared by FDA

July 1, 2019 — Catheter Precision Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its new VIVO (View into Ventricular Onset) system for market release in the United States. VIVO is a pre-procedure planning tool that offers 3-D cardiac mapping to aid in localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to electrophysiology studies. The novel VIVO system uses magnetic resonance imaging (MRI) or a computed tomography (CT) scan along with a standard 12-lead ΕCG to computer-generate color-coded 3-D mapping images of the heart to indicate the area of earliest activation.

The VIVO system consists of a handheld 3-D camera, and an off-the-shelf laptop computer with proprietary software. Using a 3-D photograph of the patient's chest, an MRI or CT (DICOM image), and a standard 12-lead ECG, the system generates a 3-D rendering of the patient's heart with superimposed color coding to indicate the area of earliest activation. VIVO uses lead positions, the chest photograph and DICOM data to determine the precise spatial relationships involved and, in that way, provide latest-generation cardiac mapping that can be used by a physician prior to conducting an electrophysiology study and subsequent ablation. The VIVO system has been shown to be 100 percent accurate (95 percent CI: 93.6 percent, 100 percent) in a prospective multi-center clinical trial. 

"VIVO is an important advance for patients who may require a cardiac ablation to better understand their irregular heart rhythms," said Hari Tandri, M.D., from Johns Hopkins University Hospital. "It is easy to use, fits into our standard workflow and is not invasive. Knowing the arrhythmia foci in advance should reduce mapping time, potentially saving procedure time and cost.  My experience with the VIVO to date has shown it to be an accurate, easy-to-use system that has the potential to significantly improve 3-D cardiac mapping technology for ventricular arrhythmia mapping."

For more information: www.catheterprecision.com


Related Content

News

Feb. 6, 2026 — Abbott has announced new clinical data from two late-breaking presentations at AF Symposium in Boston ...

Home February 06, 2026
Home
News

Jan. 20, 2026 — Abbott has received CE Mark in Europe for the TactiFlex Duo Ablation Catheter, Sensor Enabled to treat ...

Home January 22, 2026
Home
News

Jan. 20, 2026 — Kardium Inc. has announced the publication of the PULSAR clinical trial results in the Journal of the ...

Home January 21, 2026
Home
Feature | Kyle Hardner

Robotic Magnetic Navigation (RMN) emerged two decades ago as an alternative approach to performing complex ablation ...

Home January 09, 2026
Home
News

Jan. 6, 2026 — Stereotaxis, a supplier of surgical robotics for minimally invasive endovascular intervention, has ...

Home January 06, 2026
Home
News

Oct. 10, 2025 — Johnson & Johnson MedTech, in collaboration with the Heart Rhythm Clinical and Research Solutions, LLC ...

Home October 13, 2025
Home
News

Sept. 2, 2025 — Johnson & Johnson MedTech has announced acute safety and effectiveness results from the Varipure ...

Home September 05, 2025
Home
News

Sept. 3, 2025 — Kardium Inc. recently announced it has received pre-market approval (PMA) for the Globe Pulsed Field ...

Home September 03, 2025
Home
News

July 14, 2025  –  Johnson & Johnson MedTech has announced U.S. Food and Drug Administration (FDA) approval of an update ...

Home July 14, 2025
Home
News

July 7, 2025 — Catheter ablation is a minimally invasive treatment for abnormal heart rhythms. It is often successful in ...

Home July 09, 2025
Home
Subscribe Now